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BruceUla abortus injected into CBA mice replicated primarily in the spleen and liver, reaching a peak
bacterial count in both organs about 7 days postinfection. The organism was eliminated from the liver but
declined to a chronic phase in the spleen. The infection caused hepatosplenomegaly. An influx of macrophages
into the two organs was monitored by quantitative Northern (RNA blot) analysis of the macrophage-specific
marker lysozyme mRNA. Lysozyme mRNA was detectable in spleen and increased three- to fourfold during
infection. In liver, lysozyme mRNA was initially undetectable, but at about the peak of infection it reached a
level comparable to that in the spleen. Macrophage colony-stimulating factor 1 (CSF-1) has been reported to
be elevated in the circulation of animals infected with B. abortus and is known to stimulate monocytopoiesis.
To investigate the role of CSF-1 in pathogenesis, we studied the effect of further increasing the CSF-1
concentration by administration of recombinant human CSF-1. Since the infection is characterized by several
distinct phases, recombinant human CSF-1 was administered at defined times relative to these phases.
Pronounced effects were observed only when CSF-1 administration was begun during the developing acute
phase. The consequences were decreased bacterial numbers in the spleen but an increase in the liver, reduced
antibody generation, and increased hepatosplenomegaly. A feature of many chronic intracellular infections is
immunosuppression. B. abortus caused a substantial diminution of responsiveness of spleen cells to T-cell
mitogens, particularly concanavalin A. This action was mimicked by CSF-1 treatment of the animals prior to
spleen cell isolation. The results suggest that CSF-1 plays a role in macrophage recruitment in brucellosis and
that recruited macrophages contribute to the immunopathology and immunosuppression.
Brucellae are chronic infectious agents which replicate
within the cytoplasm of host mononuclear phagocytes (6).
Experimental murine brucellosis provides a useful model for
the study of many intracellular pathogens. Four stages of
infection can be identified in CBA mice: bacterial numbers
increase during the first week; a bactericidal stage concur-
rent with the onset of cell-mediated immunity follows; by
week 3, a plateau of bacterial numbers is attained; and a
recovery phase begins 5 to 6 weeks postinfection. A marked
hepatosplenomegaly, maximal at 2 to 3 weeks, is the major
pathological consequence. Immunity to infection is believed
to reside primarily in T-cell-mediated activation of macro-
phage antimicrobial activity (6). However, T-cell respon-
siveness during brucellosis is suppressed, as reflected by
reduced in vitro proliferation of spleen cells from infected
animals to mitogens and Brucella antigens (22).
The proliferation, differentiation, and mature function of
mononuclear phagocytes is regulated by macrophage colo-
ny-stimulating factor 1 (CSF-1) (23). The gene for CSF-1 in
humans and mice has been isolated (18, 21, 26), and the
human recombinant protein (which is active in mice) is
available for therapeutic evaluation. Intravenous administra-
tion of the human recombinant protein into mice causes a
dose-dependent increase in the number of tissue macro-
phages and circulating monocytes (16), the consequences of
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which are difficult to predict. In an experimental model of
melanoma, CSF-1 provided substantial protection against
pulmonary and extrapulmonary metastasis, despite its in-
ability to activate macrophage tumor cytotoxicity (15). Dis-
seminated candidiasis in mice was exacerbated by treatment
with CSF-1 administered either before or after infection (13),
and in an experimental model of arthritis in rats, CSF-1
increased joint inflammation in the acute phase and reacti-
vated the disease in the chronic phase (1).
Experimental infection of mice with Brucella abortus has
been shown to cause an elevation in circulating levels of
CSF-1 (9). CSF-1 could aid the host by increasing the
number of effector cells. Alternatively, the increase in mac-
rophage numbers could aid the pathogen by providing more
host target cells and/or by altering the nature of the immune
response. The role of CSF-1 in the pathogenesis of intracel-
lular infections of macrophages has been investigated to a
greater extent in experimental infections with Listeria mono-
cytogenes. This organism causes elevations in circulating
CSF-1, blood monocyte count, and CSF-1-responsive pro-
genitor cells in bone marrow (8). The magnitude of this
response does not vary between mouse strains that differ in
their ability to clear the organism, suggesting that it is not the
"rate-limiting" determinant of host resistance (8). One way
of testing the role of CSF-1 in intracellular infections of
macrophages is to ascertain whether artificial elevation of
CSF-1 concentration early in the infectious process alters the
course of the disease. This article is concerned with a study of
the effect of recombinant CSF-1 administration on the immu-
nopathology of experimental brucellosis in mice.
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MATERIALS AND METHODS
Mice. CBA mice were bred by the Central Animal Breed-
ing House, University of Queensland, and were kept under
conventional but disease-free conditions. Weight-matched
males, 7 to 10 weeks old, were used in all experiments.
Bacteria. B. abortus S19, originally from Commonwealth
Serum Laboratories (Parkville, Australia), was kindly pro-
vided by C. Cheers (University of Melbourne, Melbourne,
Australia). The culture was maintained by weekly subculture
on Brucella agar (Oxoid, Basingstoke, England) containing
5% heat-inactivated horse serum (Commonwealth Serum
Laboratories) and was renewed from freeze-dried stock after
20 or fewer subcultures.
Infection of mice. For the studies shown in Fig. 1 and 2,
mice were infected intraperitoneally with approximately 5 x
107 CFU of B. abortus S19. For CSF-1 therapeutic studies,
mice were injected intravenously with 100-fold fewer organ-
isms, which gave a similar pattern of infection but reduced
the variation within groups.
CSF-1 injection protocol. For most of the experiments,
human CSF-1 produced by recombinant CHO cells (a gift
from Genetics Institute Inc., Cambridge, Mass.) was used.
CSF-1 or the phosphate-buffered saline vehicle was injected
intravenously in a 0.2-ml volume in the morning on a
minimum of 4 successive days. The rationale for this proto-
col is described by Hume et al. (16). One unit of CSF-1
activity as defined for the Genetics Institute CSF-1 and
widely used for other CSFs is the amount that produces
half-maximal response in the murine bone marrow assay.
This is equal to 50 U as defined by Stanley (23) and as usually
applied to Cetus CSF-1. Other experiments were done with
recombinant human CSF-1 produced in Escherichia coli (a
gift from Cetus Corporation, Emeryville, Calif.). This prod-
uct is unglycosylated and smaller than the mammalian
recombinant protein and is cleared more rapidly from the
circulation. In preliminary experiments, we ascertained that
a dose of 100 ,ug per injection (ca. 105 U) caused a threefold
increase in peritoneal macrophage count. Neither prepara-
tion contained detectable lipopolysaccharide activity in the
Limulus amoebocyte lysate assay. We use both preparations
routinely in studies of the growth of bone marrow-derived
macrophages, a system in which CSF-1 action is blocked by
lipopolysaccharide at concentrations comparable to the sen-
sitivity of the Limulus amoebocyte lysate assay (see refer-
ence 13).
RNA preparation and Northern (RNA blot) analysis. Tissue
was removed, immediately snap-frozen in liquid nitrogen,
and stored at -20°C. The frozen tissue was placed in
ice-cold lysis buffer (6 M guanidine hydrochloride, 0.2 M
sodium acetate, 1 mM 2-mercaptoethanol [pH 5.2]) and
homogenized immediately with an Ultra-Turrax homoge-
nizer. Total nucleic acid was precipitated in 70% ethanol,
resuspended in lysis buffer plus 10 mM EDTA, reprecipi-
tated in 70% ethanol, and finally resuspended in 7 M urea-
100 mM Tris-HCl-0.1 M EDTA-0.1% sodium dodecyl sul-
fate. The nucleic acid was extracted twice with an equal
volume of phenol-chloroform (1:1) and once with water-
saturated ether, and then 2 M potassium acetate (pH 5.0)
was added to a final concentration of 0.1 M before reprecip-
itation in 70% ethanol. To extract the DNA and tRNA, the
pellet was resuspended in 2 M LiCl on ice, then resedi-
mented, and washed twice in 70% ethanol-0.1 M potassium
acetate (pH 5.0). Finally, the pellet was resuspended in 10
mM Tris-HCl-0.1 mM EDTA (pH 8.0).
Twenty micrograms of total RNA was lyophilized and
resuspended in 4.8 ,u of water. Then, 3.2 ,ul of formalde-
hyde, 10 RI of formamide, and 2 RI of 1Ox MOPS buffer [200
mM 3-(N-morpholino)propanesulfonic acid (MOPS), 50 mM
sodium acetate, 10 mM EDTA] were added, and the sample
was heated to 65°C for 10 min. Loading dye (1 [lI) containing
ethidium bromide (2 mg/ml) was added, and then the RNA
was separated on 1% agarose gels in 1 x MOPS buffer plus
3% formaldehyde. The running buffer was 1x MOPS buffer.
RNA was transferred by vacuum transfer (Vacublot; Phar-
macia) to Hybond N nylon membranes (Amersham) as
recommended by the manufacturer. Probes were labeled
with a random prime labeling kit supplied by Bresatec,
Adelaide, Australia. Probe hybridization conditions were as
recommended by the manufacturer of Hybond N mem-
branes (Amersham). The murine lysozyme cDNA probe was
a gift from Rainer Renkawitz (Munich, Germany). RNA
loading was ascertained by probing with an end-labeled
oligonucleotide corresponding to the sequence of 18S rRNA.
Lysozyme mRNA and rRNA were quantitated by scanning
the blots with an AMBIS Radioanalyzer.
DTH. To test for delayed-type hypersensitivity (DTH),
mice were challenged by injection of 10 ,ug of B. abortus
soluble antigen into the hind footpads. The antigen was
prepared by the method of Berman et al. (4) except that it
was derived from B. abortus S19 cells propagated on Bru-
cella agar with horse serum. Footpad thickness, measured
with a dial micrometer (Mitutoyo, Tokyo, Japan), was
determined immediately before and 24 h after challenge, and
footpad swelling was calculated by subtracting the initial
value from the postchallenge value.
Bacterial counts. Suspensions of infected tissues (spleen,
liver) from infected mice were prepared in a peristaltic
homogenizer (Seward Stomacher, London, England), and
serial 10-fold dilutions were plated in triplicate on Columbia
agar (Oxoid). Colonies were counted after 72 h of incubation
at 37°C.
Peritoneal cell counts. Peritoneal cells were obtained by
lavage with heparinized Hanks balanced salt solution and
enumerated in a hemacytometer.
Antibody titration. Mice anesthetized with ketamine-xyla-
zine were bled from the heart into heparinized syringes.
Plasma was obtained by centrifugation and titrated against
whole B. abortus cells by the microtiter spin agglutination
assay (27). B. abortus bacterial suspension (Commonwealth
Serum Laboratories) was added in equal volumes to micro-
titer wells containing plasma serially diluted in phosphate-
buffered saline. Following 1 h of incubation at room temper-
ature, the microtiter plate was centrifuged at 1,000 x g for 5
min. Before being read, the plate was inclined at an angle of
approximately 450 for 5 min. A positive test was character-
ized by a distinct button of agglutinated cells, whereas in a
negative test the cell pellet streamed. Results are expressed
as reciprocal titers.
Statistical analysis. The statistical significance of differ-
ences between control and CSF-1-treated groups was as-
sessed by the Mann-Whitney rank order test. The standard
error of the mean is recorded on tables and figures to give an
indication of variance, but the data, particularly for bacterial
counts, were clearly skewed towards lower values and were
not normally distributed.
Tissue culture medium. RPMI 1640 (Commonwealth Se-
rum Laboratories) was supplemented with 10 mM sodium
bicarbonate, 20 mM HEPES (N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid), 2 mM glutamine, 5 x 10-5 M
2-mercaptoethanol, and antibiotics (streptomycin [100 mg/
liter] and penicillin [105 U/liter]).
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FIG. 1. Time course of infection and changes in spleen and liver
weights in Brucella-infected mice. Means are the average + stan-
dard error (SE) for four animals from two separate experiments.
Lymphocyte proliferation assays. Single-cell suspensions
were prepared from spleens excised from untreated controls
or from mice 5 days after infection or commencement of
CSF-1 administration, by teasing tissue through stainless
steel mesh into cold RPMI. Erythrocytes were removed by
ammonium chloride lysis. Cells (2 x 105) were added to each
U-bottomed microtiter well in 200 ,ul of RPMI with 2%
normal mouse serum plus dilutions of phytohemagglutinin
(PHA; Sigma, St. Louis, Mo.) or concanavalin A (ConA;
Calbiochem, La Jolla, Calif.). After 24 h of incubation, each
culture was pulsed with 37 kBq of [methyl-3H]thymidine
(Amersham, Buckinghamshire, England) for 16 h. Cells were
then harvested onto glass fiber filters, and incorporation of
the radiolabel was quantitated by liquid scintillation spec-
troscopy. All determinations were done in triplicate.
RESULTS
Bacterial infection time course. Figure 1 shows a time
course of infection in animals infected with B. abortus. The
patterns observed in the two major organs affected, the liver
and spleen, were somewhat different. Peak bacterial num-
bers were reached very rapidly in the spleen, within 2 days
of infection, and remained stable until day 8, when they
started to decline rapidly. In the liver, bacterial numbers
rose more slowly, reaching a peak on day 6 at a higher level
than observed in the spleen, and then declined much more
rapidly, so that by day 14 the numbers approached the limits
of detection. These data are essentially compatible with
those of Cheers (6).
Hepatosplenomegaly. Both the spleens and the livers of
infected animals increased in weight during infection (Fig.
1). Spleen weight had increased twofold by day 6 and
increased a further fourfold by day 14. Liver weight was
stable up until day 6 but increased by approximately 50% by
day 14. Note that the largest increases in weight in both
organs appear to correlate with the resolution of the infec-
tion (Fig. 1).
Northern analysis of mRNA expression in infected organs.
In order to gain some insight into the role of macrophages in
hepatosplenomegaly, we isolated RNA from the livers and
spleens of Brucella-infected animals at various times postin-
fection and investigated the expression of macrophage-
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FIG. 2. Effect of Brucella infection on expression of lysozyme
mRNA in the liver and spleen. Northern blotting and hybridization
of tissue RNA prepared from animals on the day indicated were
performed as described in Materials and Methods. The radiolabel
(counts per minute) associated with the lysozyme-specific band was
quantitated with an AMBIS Radioanalyzer and is corrected relative
to the labeling intensity of the 18S RNA band on the same sample.
Results are the average of duplicate spleens (A) and livers (B)
processed from separate infected animals.
specific mRNAs. In granulocytes and other cell types,
lysozyme is stored in cytoplasmic granules, and the mRNA
is not abundant. By contrast, macrophages produce the
protein constitutively and secrete it into the extracellular
medium. Lysozyme mRNA has been reported to be very
abundant in murine macrophages but not in granulocytes (5,
10). We have confirmed that lysozyme mRNA is expressed
in primary mouse macrophages and macrophagelike tumor
cell lines at very high levels, comparable to ,B-actin (data not
shown). Because of this abundance, lysozyme mRNA can be
detected in total RNA from whole organs even though
macrophages represent a relatively small percentage of the
total cell number.
Lysozyme mRNA was detectable in control spleen, in-
creased substantially by day 2 to day 4 postinfection, and
reached an apparent peak by days 6 to 8 (Fig. 2A). In control
liver, no lysozyme mRNA could be detected, but the level
approached that of infected spleen by days 6 to 8 postinfec-
tion. The blots used for lysozyme analysis were reprobed
with cDNA encoding c-fins, the receptor for CSF-1, and
urokinase plasminogen activator, a CSF-1-inducible gene
(13). No band was detectable in control liver or spleen, but
bands of the expected sizes were obtained with liver and
spleen samples taken on days 6, 8, 11, and 14 (data not
shown). The signal was below the limits of accuracy of the
AMBIS Radioanalyzer and was not quantified. Neverthe-
less, the observation supported the conclusion that substan-
tial macrophage infiltration of both organs occurred during
the infection.
Effect of treatment with CSF-1 on Brucella infection. Be-
cause macrophage infiltration of the spleen and liver corre-
lated with reduced bacterial count, and because CSF-1
administration can cause macrophage infiltration into both
sites (16), animals were treated with recombinant CSF-1 to
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TABLE 1. Effect of CSF-1 pretreatment on Brucella infectiona
Liverwt Spleen ~~~~~~~~DTHAgglutinating B. abortusGroup Liver wt Spleen (footpad antibody (106 CFU/Group
~~~~~(mg)wt (mg) swelling,pLm)tiespen
Control 1,504 + 54 128 ± 9 11 ± 6 11.6 ± 1.6 3.9 + 1.4
CSF-1 treated 1,561 ± 64 112 ± 8 45 ± 14 5.0 ± 0.5 2.4 ± 0.7
a Animals were injected intravenously with recombinant human CSF-1 on each of the 4 days preceding intravenous infection with 5 x 105 B. abortus organisms.
Results are expressed as the mean ± SE (n = 6). The differences between control and treated animals are not significant (P > 0.05).
see whether it would hasten the resolution of the disease.
Since the time course of experimental brucellosis exhibits a
series of well-marked phases, CSF-1 was administered at
several defined times in relation to the initiation of infection.
When CSF-1 was given to mice on 4 consecutive days (days
-4, -3, -2, and -1) prior to infection (on day 0), there was
no significant effect on total body weight, liver and spleen
weight, DTH reaction, antibody titer, or bacterial count in
the spleen. Measurements were made on day 7, during the
acute phase, and the results are shown in Table 1. Slight
decreases in the mean values for bacterial load and antibody
were not significant (P > 0.05) by the Mann-Whitney
method. The normal mouse spleen weight (80 ± 8 mg
[standard deviation]) was increased by the infection but was
not further influenced by CSF-1 in this experiment. Thus,
CSF-1 had no definable prophylactic activity. This result
implies that the effect of CSF-1 is reversible, in that the
increased spleen weight observed when animals are killed on
the day after the last CSF-1 injection (see reference 16 and
Table 2) was no longer evident 7 days later.
Effect of CSF-1 administration at time of infection. Treat-
ment with CSF-1 commencing at the time of infection (day 0)
did alter several parameters. Again, the CSF-1 was admin-
istered on 4 consecutive days, and the results on day 7 for
three separate experiments are shown in Table 2. The
efficacy of the CSF-1 was demonstrated by a three- to
fourfold increase in peritoneal cell number, as observed
previously in uninfected animals (16) and confirmed in
uninfected controls assayed in parallel (not shown). CSF-1
also increased spleen mass above the approximate doubling
caused by Brucella infection itself. The magnitude of the
increase was similar to that reported in an earlier study of
uninfected animals (16). Neither Brucella infection nor
CSF-1 alone caused any change in liver weight at this time
point compared with that in three untreated animals proc-
essed at the same time (data not shown, but see also day
6/day 8 time point in Fig. 1). They did cause a 15 to 20%
increase in combination.
The bacterial counts in the two organs changed in opposite
directions. The count in the spleen decreased significantly in
one of three experiments and was unaffected in the others.
Conversely, the bacterial count in the liver was increased
five- to sixfold by CSF-1. At this early stage in infection,
DTH and antibody responses were still quite low. The DTH
response was unchanged by CSF-1, but the agglutinating
antibody titer was reduced twofold. Note that the third
experiment in Table 2 was performed with the bacterial
CSF-1 from Cetus with essentially the same result. In this
third experiment, we also looked at the lungs, another site
for macrophage-mediated clearance of intravenous inocula.
There were far fewer organisms in the lungs than in liver and
spleen. Lung weight and bacterial load ofBrucella organisms
were unaffected by CSF-1. There was also no change in the
number of endogenous floras obtained on the assay plates.
Effect of CSF-1 treatment during chronic phases. As shown
in Fig. 1, the bacterial count in the spleen and liver was much
reduced by day 14 postinfection. This decline in the number
of organisms was correlated with potent antibody and DTH
responses, which were sustained for an extended period
(Table 3). It seemed inherently unlikely, given the elevation
in CSF-1 mRNA in liver and spleen and the reported
increase in biological activity in the circulation (9), that
addition of more CSF-1 would alter any parameters of
infection or pathogenesis. However, the presence of CSF-1
does not necessarily mean it is saturating for mononuclear
phagocyte receptors. If it was not, we believed that admin-
istration late in infection could reactivate bacterial replica-
tion by providing naive target cells.
TABLE 2. Effect of concurrent CSF-1 treatment on Brucella infectiona
DTH P-ioelB. abortus countsGroup and Liver wt Spleen wt Lung wt (footpad Antibody Peritoneal B._abortus_counts Total flora (104
expt no. (mg) (mg) (mg) swelling, titer macroh6ages 106 CFU/i ) CFU/ 104 CFU/ CFUflung)
,um) (10) spleen liter lung
Control
I 1,424 110 145 8 122 6 64 18 90 12 1.4 ±0.3 7.7 1.1
II 1.503 38 173 9 15 6 37 5 2.1 0.5 11.0 3.7 6.4 ± 0.9
III 1,444 32 173 12 35 7 30.0 5 15.0 ± 3.0 14.0 ± 12.0 18 ± 7
CSF-1 treated
I 1,765 64b 226 11c 133 7 41 14 35+ 6 5.1 +1.6 3.6 0.6c
II 1,833 ± 22C 254 ± 10C 24 ± 11 17 ± 2C 7.3 ± 1.2c 8.7 ± 2.7 24.9 ± 7.4C
III 1,511 46 216 ± 12b 42 ± 13 32 6 71.0 ± 8.0c 2.3 ± 0.8 11 ± 4
a CSF-1 treatment was begun on the same day as injection of 5 x 105 B. abortus organisms and continued daily for 4 days. Animals were killed on day 7
postinfection. Results are expressed as the mean ± SE (n = 10) and derive from three independent experiments (I, II, and III). CSF-1 from the Genetics Institute
was used for experiments I and II, and CSF-1 from Cetus was used for experiment III.
b p < 0.05 versus control.
c P < 0.01 versus control.
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TABLE 3. Effect of CSF-1 treatment during chronic phase of Brucella infectiona
DTH Peritoneal B. abortusGroup and Liver wt Spleen wt (footpad Antibody macrophages (104 CFU/
exptno. (mg) (mg)
~~~~~swelling, xLm) ter(106) spleen)
Control
I 1,534 ± 45 280 + 36 222 ± 38 1,280 ± 143 1.3 ± 0.6 6.7 ± 2.4
II 1,674 ± 75 175 + 12 152 + 35 1,061 ± 189 2.3 ± 1.0
CSF-1 treated
I 1,619 ± 52 305 ± 18 135 + 46 1,052 ± 71 1.8 ± 0.6 2.6 ± 1.4
II 1,673 69 217 29 219 25 640 134 1.8 ± 1.4
a Treatment with CSF-1 was begun on either day 35 (experiment I) or day 46 (experiment II) postinfection. In experiment I, treatment was given for 4 days,
and the animals were killed on the seventh day. In experiment II, treatment was given for 6 days, and the animals were killed on the seventh day. Results are
means + SE (n = 10). Differences between control and CSF-1-treated groups are not significant (P > 0.05).
In the first experiment, CSF-1 was given on 4 consecutive
days beginning on day 35. In the second experiment, an
attempt was made to amplify the small effects by treating
more often (on 6 days) and starting later (day 46), when the
bacterial count had fallen further. There were no convincing
changes observed in response to CSF-1 in spleen mass,
DTH, or antibody titer, all of which were already greatly
elevated. The bacterial count in the spleen was also not
significantly reduced. By this time, bacteria in the liver were
undetectable. Most importantly, there was no detectable
effect of CSF-1 on peritoneal cell numbers, suggesting that
the animals were no longer responsive to additional exoge-
nous ligand.
Time course of suppression of lymphocyte proliferation by
infection. The data thus far suggested that elevation of
plasma CSF-1 was not sufficient to hasten the clearance of
bacteria from the spleen and liver. In fact, they are more
consistent with a role in recruitment of target cells and the
generation of hepatosplenomegaly. Accordingly, CSF-1
might play a role in another well-defined index of the
immunopathology of brucellosis. Immunosuppression is a
common feature of chronic intracellular infections, which
manifests in a decreased responsiveness to T-cell mitogens.
The ability of macrophages from Brucella-infected mice to
inhibit mitogen responses of splenic T lymphocytes has been
reported previously (22). Since there is abundant evidence
that different T-cell mitogens affect different cell populations
(17), we looked at the different effects of B. abortus on
spleen cell responsiveness to two different mitogens, ConA
and PHA, at a range of concentrations.
Responsiveness to all concentrations of ConA was se-
verely diminished in spleen cells from animals assayed 10
and 20 days after Brucella infection but was restored, with
low-dose enhancement, by day 30 postinfection (Fig. 3).
Inhibition of proliferation in response to PHA was not as
severe. There were small changes in the dose-response
curves at days 5 and 10 postinfection, but by day 20 the
response was greater than in control spleen cells (Fig. 4).
Since B. abortus alone was capable of producing substantial
immunosuppression, there was little point in assaying the
effect of CSF-1 therapy. We therefore asked whether CSF-1
alone could produce a similar suppression of mitogen re-
sponses. Figures 3 and 4 (day 5) show that the alteration of
spleen cell proliferative responses to ConA and PHA caused
by treatment of mice with CSF-1 was even more pronounced
than seen during Brucella infection. In the microcultures, the
increased number of macrophages in the spleens of CSF-1-
treated animals was visibly obvious, with numerous cells
attached to the sides of the U-shaped wells (not shown).
Both ConA and PHA responses were greatly inhibited. As
seen in Brucella-infected spleens, the optimal concentration
of ConA was also reduced (from 5 to 1 ,ug/ml).
DISCUSSION
The results address some aspects of the role of CSF-1 in
the pathogenesis of a chronic intracellular infection, explor-
ing in the process any possibility of a therapeutic application.
The time course of Brucella infection was shown to differ
between the two major involved organs (Fig. 1). In the spleen,
the infection peaked early and declined to a plateau of about
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FIG. 3. Dose-response curves for ConA-induced proliferation at
various times postinfection. Spleen cells from infected mice (A),
uninfected control mice (0), and mice treated for 4 days with CSF-1
(-; assayed in parallel with day 5 infection samples) were tested.
Points and bars represent means - SE (n = 4).
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FIG. 4. Dose-response curves for PHA-induced proliferation at
various times postinfection. Spleen cells from infected mice (A),
uninfected control mice (0), and mice treated for 4 days with CSF-1
(A; assayed in parallel with day 5 infection samples) were tested.
Points and bars represent means + SE (n = 4).
5 x 104 organisms per spleen. This low level of infection can
be sustained for a very long time, as documented by others
(6) and as evidenced by the data in Table 3. By contrast, the
liver reached a peak of infection later, but the number of
organisms dropped much more rapidly. Essentially, the
infection of the liver resolved completely. In both sites,
there was clear evidence of substantial macrophage infiltra-
tion, as evidenced by expression of the macrophage-specific
marker lysozyme mRNA (Fig. 2). Increased lysozyme
mRNA expression was correlated with a rapid increase in
weight in both the spleen and liver, suggesting that macro-
phage influx contributes to hepatosplenomegaly.
The time course of appearance of CSF-1 in the circulation
of infected animals (9) parallels the major increase in hep-
atosplenomegaly commencing at about day 7. The ability of
exogenous CSF-1 to increase macrophage numbers in the
peritoneal cavity, liver, and spleen and to increase spleen
weight has been documented before (16). Liver weight was
not previously measured. CSF-1 alone did not cause in-
creased liver weight (data not shown), but' it accelerated the
increase brought about by Brucella infection (Table 2). A
possible interpretation is that the Brucella organisms provide
a chemoattractant to direct the monocytes recruited by
CSF-1 treatment to the site of infection. Supporting this
concept, peritoneal cell macrophage numbers were not af-
fected by intravenous infection with B. abortus (the unin-
fected control for Table 1 is about 1 x 106 to 2 x 106 per
animal), but intraperitoneal infection with B. abortus can
cause a 10-fold increase in peritoneal macrophage numbers
(data not shown).
Only when CSF-1 was administered during the developing
acute phase were the consequences marked; administration
before infection or during the chronic phase had much less
effect on any variable measured. The failure of pretreatment
to influence bacterial growth or immunity suggests that
CSF-1-stimulated macrophages are not cytocidal towards B.
abortus. Similarly, Cheers et al. (7) found that CSF-1 treat-
ment of macrophages in vitro increased the uptake of L.
monocytogenes but did not alter cytocidal activity. When
CSF-1 was given to mice commencing at the time of infec-
tion, the bacterial count in the spleen was reduced slightly in
spite of the increase in spleen weight. Since an influx of
macrophages contributes significantly to splenomegaly, a
reduced or even an unchanged count would imply a consid-
erable reduction in the number of bacteria per macrophage if
all the organisms were intracellular. However, we are not
able to confirm this proposal, and indeed, a possible mech-
anism for chronic infection of the spleen might involve
Brucella survival in a nonmacrophage compartment. We
have not monitored bacterial numbers for a more extended
period following CSF-1 therapy to see whether the rate of
clearance of organisms was accelerated subsequently.
In the liver, the bacterial count was increased substan-
tially by CSF-1 treatment (Table 2). The magnitude of the
change was similar to the approximate change in macro-
phage numbers measured in the peritoneum of the infected
animals. Hence, the simplest explanation would be that
CSF-1 increased the number of target cells without greatly
altering their function or the rate of replication of B. abortus
in any particular cell. If so, the question is why the same
thing does not happen in the spleen. Apart from the possi-
bility that the organisms in the spleen are not actually
intracellular (see above), there could also be differences in
macrophage function between the two organs. One differ-
ence is that CSF-1 mRNA is already readily detectable in the
uninfected spleen but not in the liver (2a). If CSF-1-stimu-
lated macrophages are the optimal host cells for the organ-
ism, this might explain why bacterial numbers are twofold
higher in spleen than in liver by 2 days postinfection (Fig. 1)
despite the fact that the liver is by far the most important
organ in terms of macrophage-mediated clearance activities
(14). For example, in the clearance of CSF-1 itself, 89% of
radiolabeled CSF-1 is cleared by endocytosis in the liver,
whereas only 6% is cleared by the spleen (3).
The data in Table 3 imply that the effects of Brucella
infection and exogenous CSF-1 treatment on liver and spleen
weight are not additive. There was no evidence that CSF-1
reactivated bacterial replication once it had entered a
chronic phase. From a therapeutic viewpoint, this is not a
trivial observation. The failure of CSF-1 to induce increased
peritoneal cell numbers in the chronically infected animals
suggested that they were resistant to the treatment. One
explanation is that the CSF-1 concentration in the circulation
is already very high, and the receptor pool is saturated. An
alternative is that the macrophage pool is very greatly
enlarged and the injected CSF-1 is much more rapidly
cleared by receptor-mediated endocytosis (3). Finally, it
could be that biological effectors generated by either the
organism or the immune system block the action of CSF-1.
We have no evidence to distinguish among these alterna-
tives.
The reduced antibody titers seen in acutely infected
animals (Table 2) suggest a decrease in immune function as
a result of CSF-1 treatment. A possible mechanism for this
would be the immunosuppression brought about by in-
creased macrophage numbers. These cells are known to
0
E0.4
0C
a
0
co
0
CL0
c
E
I
CD
INFEcr. IMMUN.
 o
n
 Septem
ber 18, 2016 by UQ Library
http://iai.asm
.org/
D
ow
nloaded from
 
CSF-1 IN EXPERIMENTAL BRUCELLOSIS 1471
downregulate immune responses under some conditions,
prostaglandin release being a commonly implicated mecha-
nism (11). The slight reduction in bacterial numbers in the
spleens of CSF-1-treated mice is unlikely to influence anti-
body production by limiting the supply of bacterial antigens,
particularly as these are known to be highly immunogenic.
The protective role of antibody in murine brucellosis has
been repeatedly demonstrated (19, 20), and this is probably
due largely to enhancement of phagocytic capacity by op-
sonization (2). CSF-1 increases expression of the Fc recep-
tor type III subclass on macrophages in vitro, which could
potentially enhance the uptake of opsonized bacteria (28).
However, this would bring little therapeutic benefit if the
agent simultaneously reduced antibody production. As
shown in Fig. 3, CSF-1 injection alone can mimic the ability
of Brucella infection to suppress the responsiveness of
spleen cells to T-cell mitogens. This finding in vivo parallels
a report that CSF-1-stimulated peritoneal macrophages
added to spleen cells markedly inhibited the response to
T-cell mitogens (25). In addition, the course of suppression
of lymphocyte proliferation by infection correlates closely
with elevation of serum levels of colony-stimulating factors
in infected mice: macrophage colony-stimulating activity
was elevated at 7, 14, and 21 days postinfection, returning to
normal by day 28 (9, 22). This evidence suggests that
endogenous CSF-1, which is produced in response to Bru-
cella infection, could contribute to the suppression of mito-
genic responses. A possible mechanism is suggested by the
discovery that CSF-1 increases production of a specific
inhibitor of interleukin-1 action by murine macrophages (24).
In this context, the selectivity of inhibition of mitogenesis
in Brucella infection towards ConA-responsive spleen cells
is of interest. Hume and Weidemann (17) reviewed the
evidence that ConA and PHA stimulate different, though
overlapping, T-cell populations. Cells responding to low
doses of ConA correlated with CD4-positive helper T-cell
activity, whereas depletion of CD8-positive cells reduced
PHA responsiveness. Conversely, depletion of Fc receptor
or major histocompatibility complex class II-positive cells
from splenocytes left a residual population that responded
only to PHA. Without performing specific studies with T-cell
surface markers, we do not wish to overinterpret the present
results except to say that they are consistent with a selective
effect of Brucella infection on subpopulations of T cells in
the spleen. The effect of CSF-1 was rather less specific in
that both PHA and ConA responses were greatly reduced
(Fig. 3 and 4). Spleen cells from CSF-1-treated animals also
fail to stimulate or respond in a one-way primary mixed
lymphocyte reaction to allogeneic cells (13a). Of course, the
situations in a Brucella-infected and a CSF-1-treated spleen
are not comparable. In the infected spleen, the increase in
macrophage content must be accompanied by an influx of
other cell types, so that the relative percentage of macro-
phages may not change greatly (as evidenced by the data in
Fig. 2).
The results suggest that macrophage numbers and the
production of CSF-1 are not limiting in the control of
infection with an intracellular pathogen such as B. abortus in
the sense that increasing them produces no beneficial effect.
This is in conceptual agreement with data from experimental
Listeria infection, in which genetic variation in resistance
between mouse strains could not be correlated with CSF-1
production or action (8). In fact, it appears that the ability of
B. abortus and similar agents to induce CSF-1 is a positive
virulence determinant, leading to an increase in the number
of susceptible target cells (at least in some organs) and
suppressing the development of T-cell-mediated immune
responses. Given these results, it will be of particular
interest to ascertain whether CSF-1 influences the formation
of granulomas, the most common manifestation of chronic
intracellular infections.
In other systerns, experimental candidiasis and strepto-
coccal arthritis, CSF-1 administration aggravates the pathol-
ogy (1, 13). In each case, there is other substantive evidence
that macrophages are responsible for the pathology and that
local CSF-1 production occurs. If increased CSF-1 produc-
tion does play a role in pathogenesis, therapeutic applica-
tions could be envisaged for neutralizing antibodies against
CSF-1 (12). However, the effect of such antibodies would be
very difficult to control and to interpret because of the role of
CSF-1 in the production and continued viability of macro-
phages in the steady state (3, 23) and the probable multiple
roles of the macrophage in infection, as a host cell for
bacterial replication and an effector cell in bacterial elimina-
tion and pathogenesis.
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